CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig® (ponatinib) and brigatinib (AP26113), its investigational anaplastic lymphoma kinase inhibitor, will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, May 29 to June 2, 2015.
Help employers find you! Check out all the jobs and post your resume.
